Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 29, 2026, 7:00 AM ET
Incyte reported third quarter 2026 total revenue of $1.56 billion, up 14% year over year, and raised its 2026 guidance for Opzelura, Hematology and Oncology, and total net sales.
Nasdaq: $INCYCommercial biopharmaceuticalsJakafi and late-stage developmentPatent, launch and acquisition risk
INCY Stock Hub: Incyte News, Jakafi and the Late-Stage Pipeline
Growth outside Jakafi must be weighed against its expected 2028 U.S. exclusivity loss. The September quarter shows stronger net sales and a large acquisition-related accounting charge; clinical windows and regulatory decisions remain separate. The October 30 regular-session close was $120.39 (+3.07% versus October 29).
Full research report · PDF
Incyte ($INCY), research as of October 29, 2026
18 pages covering Jakafi exclusivity, Opzelura accounting, commercial diversification, late-stage pipeline, acquisitions, September results and capital allocation. This is a dated research snapshot; the hub follows later developments. For personal use only: redistribution prohibited.
Next company-guided clinical windows
Q4 2026 · separate Phase 3 and regulatory milestones
Incyte guides to Phase 3 povorcitinib prurigo nodularis and ruxolitinib-cream hidradenitis suppurativa data in Q4, alongside a European Commission decision on povorcitinib in HS. No exact days are announced. October 29 business update
The company anticipates potential U.S. approval and launch of povorcitinib in HS and Monjuvi in newly diagnosed DLBCL in Q1 2027; those remain conditional expectations.
INCY stock at a glance
Close · October 30, 2026
$120.39
Regular session; +3.07% versus $116.80 on October 29. USD.
Cash + securities — at September 30, 2026
$3.9B
At Sep 30, 2026, after the $1.25B Vega cash closing in July; $4.5B at Jun 30, 2026 Primary source
Q3 GAAP net loss
$784.8M
$3.86 per share; includes a one-time $1.23B IPR&D expense for Vega ($585.6M net income in Q2) Primary source
Opzelura Q3 sales
$255M
+36% YoY; Q2 was $449.7M, including a $246M CMS-related non-cash benefit Primary source
Shares out — at October 22, 2026
203.8M
As of Oct 22, 2026 (Q3 10-Q cover, 203,832,492 shares) · Primary source
2026 sales guidance
$5.21–5.30B
Raised from $5.13–5.26B after Q3
Where Incyte stands now
Incyte’s October 29 results raised full-year net-sales guidance to $5.21–5.30B. Quarterly Jakafi sales were $827M and Opzelura $255M. The GAAP loss includes the Vega IPR&D charge; it should not be confused with an equivalent quarter of recurring cash consumption. Third-quarter results
A funded pipeline still has to replace future patent exposure with durable commercial returns. Clinical failure, regulatory review, product access, acquisition economics and the timing of replacement revenue can weaken the post-Jakafi case. One-time accounting effects must be separated from recurring sales and operating costs.
The constructive case
Incyte combines an established Jakafi franchise with growing dermatology and oncology products. Q3 revenue was $1.557 billion, up 14%, with a GAAP net loss of $784.8 million that includes a one-time $1.23 billion IPR&D expense related to Vega; Opzelura net sales were $255 million, up 36%. In Q2, revenue had been $1.674 billion with $585.6 million of GAAP net income, and removing Opzelura’s $246 million non-cash benefit left approximately $204 million of quarterly Opzelura sales, up 24% year on year. Successful launches and clinical readouts could diversify the business before Jakafi’s expected 2028 loss of exclusivity.
The cautious case
Jakafi generated $827 million of Q3 sales ($816.7 million in Q2) and remains the principal franchise. New products must replace a large revenue base, while the $1.25 billion Vega acquisition consumes resources ahead of later clinical milestones. The Opzelura accounting benefit is not recurring demand, and a profitable quarter does not settle the patent-cliff or pipeline risks.
Latest Incyte news
October 29, 2026
Third-quarter sales grow and guidance rises
Total revenue was $1.56B and net sales $1.32B. The GAAP net loss included a $1.23B acquired IPR&D charge; net-sales guidance rose to $5.21–5.30B.
October 28, 2026
Combination study doses its first participant
Partner Adagene announced the first participant in a Phase 1 study of muzastotug with INCA33890 in MSS colorectal cancer. First dosing is not an efficacy result.
October 26, 2026
ESMO data update advances the GI oncology program
Early INCB161734 and INCA33890 findings support ongoing and planned studies. Early response observations and future registrational evidence remain distinct.
October 24, 2026
Genmab clinical collaboration announced
The planned Phase 1/2 combination evaluates INCB161734 with petosemtamab and chemotherapy in KRAS G12D-mutated colorectal cancer. A collaboration is not demonstrated patient benefit.
October 18, 2026
ESMO presentation and investor schedule announced
The earlier notice set scientific presentations and the October 26 investor event. Both are now past; the later data update provides the reported findings.
September 25, 2026
Atebrioz approved for FOP from age twelve
The approval covers the specified FOP population. The announcement expected October U.S. availability, without an exact day; approval and actual launch remain separate.
INCY stock catalysts and dated milestones
- Q4 2026 — STOP-PN1/2 and TRuE-HS1/2 Phase 3 data targeted. Company windows
- Q4 2026 — European Commission decision on povorcitinib in HS anticipated. Pending regulatory decision
- By year-end 2026 — Phase 2 asthma topline targeted. Company window
- Q1 2027 — Potential U.S. approvals and launches described for povorcitinib HS and Monjuvi frontline DLBCL. Conditional company expectations
INCY Jakafi and the diversification test
Jakafi remains the largest commercial product and its expected 2028 U.S. exclusivity loss frames the diversification challenge. Opzelura growth, hematology and oncology launches, pipeline readouts and acquisitions provide different routes to replacement revenue. Their timing, costs and probability of success cannot be treated as interchangeable.
Incyte earnings: operating growth and the Vega accounting charge
September-quarter total revenue was $1.56B and net sales $1.32B. The $784.8M GAAP net loss includes a one-time $1.23B IPR&D charge associated with Vega. Cash and marketable securities of $3.9B follow the July cash closing; acquisition accounting, commercial sales and cash movement answer different questions.
Merlintrader Health Score · $INCY
4.25out of 5
Assessed October 4, 2026; financial inputs through October 29. Weighted calculation: 4.5×30% + 4.0×30% + 4.5×20% + 4.5×10% + 3.5×10% = 4.25. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- Jakafi exclusivity loss is a future commercial exposure.
- A large acquired IPR&D charge is not recurring quarterly cash burn.
- Guided readouts and potential launches are not completed approvals.
INCY Stock FAQ: Incyte Questions Answered
Did Incyte report a profit in the September quarter?
It reported a $784.8M GAAP net loss, including a one-time $1.23B Vega-related IPR&D charge. This differs from the profitable June quarter. September results
What does the Jakafi cliff refer to?
The expected loss of U.S. exclusivity in 2028 and the need to build replacement earnings.
Is all Opzelura growth recurring?
Product growth must be separated from the $246M CMS-related reserve benefit included in the June quarter. The September quarter had its own $255M product-sales figure.
How much liquidity was reported?
Cash and marketable securities were $3.9B at September 30, following the Vega closing. This is a dated financial balance.
Are the Q4 pipeline events approvals?
Some are planned data readouts and others pending regulatory decisions. Each program has its own evidentiary and regulatory pathway.
Primary sources
- October 29, 2026 — Third-quarter sales grow and guidance rises
- October 28, 2026 — Combination study doses its first participant
- October 26, 2026 — ESMO data update advances the GI oncology program
- October 24, 2026 — Genmab clinical collaboration announced
- October 18, 2026 — ESMO presentation and investor schedule announced
- September 25, 2026 — Atebrioz approved for FOP from age twelve
Disclaimer: This content is provided for informational and educational purposes only and does not constitute financial advice, investment advice, a recommendation to buy or sell any security, or personalized portfolio guidance. Biopharmaceutical stocks are volatile and involve substantial risk, including the loss of principal; outcomes depend on clinical, regulatory, commercial and patent-related events that can change quickly. Figures in this report are stated as of the dates indicated and are drawn from SEC filings, company releases and other primary sources. Readers should perform their own due diligence and consult a qualified, licensed financial professional before making any investment decision.
